Pompano Beach, FL, April 14th, 2020 — BioStem Life Sciences, a wholly owned subsidiary of BioStem Technologies, Inc. (OTC PINK: BSEM) (“BioStem” or the “Company”), and a certified full-service GMP contract development and manufacturing organization, with a focus in perinatal tissue-based medical products, today announced that it had launched a new website at www.BioStemLifeSciences.com. [Read more…]
Cord Blood
Because cord blood present within a newborn’s umbilical is rich with stem cells, it can be collected and stored for future medical use.
COVID-19 Diagnostic Kits: Total Number, Types and Speed
As of today, 41 laboratory COVID-19 diagnostic tests have been authorized by regulators to identify the virus. In the U.S., these tests are supplied by the CDC for the state and local public health departments and private medical providers are getting tests developed by the commercial manufacturers. The U.S. government did not issue guidance allowing commercial labs to process COVID-19 tests until February 29, 2020, after which the companies began testing within a week.
Currently, 20 COVID-19 diagnostic kits from the U.S. manufacturers have won the emergency use authorization (EUA) from the FDA. [Read more…]
TreeFrog Therapeutics brings in senior profiles to drive the advent of high-quality & affordable allogenic cell therapies
Senior profiles from Merck KGaA and FUJIFILM Cellular Dynamics join in to accelerate the global dissemination of proprietary C-StemTM technology for cell therapy mass-production.
Bordeaux, France, February 5, 2020 – TreeFrog Therapeutics, a pure player in iPSC-derived cell therapies, today announces the appointment of 2 senior executives and 2 independent board members. Pascale Berthet, formerly Business Development Manager at FUJIFILM Cellular Dynamics was appointed Chief Business Development Officer, and Michaël Lanero Fidalgo, former Head of EMEA Biodevelopment Center at Merck KGaA, was recruited as Chief Operating Officer. In addition, 2 independent board members joined TreeFrog Therapeutics’ corporate governance: Julia Berretta, formerly VP of Business Development at Cellectis, and Frederic Desdouits, former Bionest Partner and Pierre Fabre North America director. [Read more…]
International Perinatal Stem Cell Society to Host Two Scientific Conferences in 2020
The International Perinatal Stem Cell Society is a non-profit organization founded on the principle that stem cells from perinatal tissues contain enormous, untapped potential to treat many diseases and disorders worldwide.
For many years, the Perinatal Stem Cell Society has been hosting an annual conference featuring the world’s leading perinatal stem cell researchers, specializing in Amnion, Amniotic Fluid, Cord Blood for Regenerative Medicine, Cord Tissue, and the Placenta. Its scientific programs cover all aspects of the perinatal stem cell field, with opportunities to learn from leading clinicians utilizing cellular therapies within their practices.
Below, Kyle Cetrulo, President of the International Perinatal Stem Cell Society, explains the future of perinatal stem cell science and the role that the Society’s 2020 Scientific Conferences will play in advancing this mission. [Read more…]
CBR Announces New Pediatric Genetic Screening Test in Collaboration with Sema4
Sema4 collaborated with CBR to launch ReadyGen™, a genetic screening test that analyzes a child’s DNA for 200+ conditions.
LOS ANGELES, Nov. 15, 2019 — CBR, the global leader in newborn stem cell banking, has announced a new genetic service developed over the past couple of years as part of a strategic alliance with Sema4. As a patient-centered health intelligence company and leading innovator within the genomic testing industry, Sema4 collaborated with CBR to launch ReadyGen™, a highly accurate genetic screening test that analyzes a child’s DNA for more than 200 conditions that can affect children before the age of 10. [Read more…]
- « Previous Page
- 1
- …
- 25
- 26
- 27
- 28
- 29
- …
- 62
- Next Page »